A plant biotechnology approach leveraging prion-like domains in endosomal proteins (LIP5, ALIX, FREE1) to enhance abscisic acid signaling and drought tolerance. Overexpression of LIP5 in maize aims to improve water usage efficiency, offering a novel genetic strategy for climate-resilient crop development.
This research program targets improved drought tolerance in crops by exploiting prion-like domains (PrLDs) found in plant endosomal proteins. The team has identified that three Arabidopsis proteins—LIP5, ALIX, and FREE1—contain prion-like domains that regulate abscisic acid (ABA) signaling and drought responses through control of vacuolar protein sorting and degradation. The core hypothesis is that overexpressing LIP5 in maize will enhance water usage efficiency and drought resilience by modulating endosomal activity and ABA receptor stability.
The work addresses a critical agricultural challenge: developing crops that maintain yield under water-limited conditions. By leveraging a plant-specific molecular mechanism (prion-like behavior in endosomal proteins), this approach offers a differentiated strategy compared to conventional drought-tolerance traits.
Key biological features:
Maize validation strategy:
The technology is at an early-to-mid stage of development. Proof-of-concept has been established in Arabidopsis, where LIP5 overexpression and ALIX/FREE1 mutations have demonstrated enhanced drought tolerance and ABA hypersensitivity. The prion-like properties and phase-separation behavior of LIP5 are under active investigation through ongoing collaborations. Current work involves generating transgenic maize lines and initiating greenhouse and field validation studies to confirm that LIP5 overexpression improves water usage efficiency in a crop species, and that PrLD-driven phase separation is required for this effect. Further validation is needed before commercial application.
The University of Wisconsin–Madison is the state’s flagship public research university, a comprehensive institution with a large research enterprise and broad disciplinary breadth. Industry engages through shared instrumentation, pilot‑scale testbeds, and co-located core facilities that support prototyping and scale-up. An affiliated research and technology park hosts startups and corporate R&D, while integration with a major hospital system enables clinical translation; a statewide extension network connects campus advances to companies and communities across Wisconsin. Research is sustained by competitive federal funding from agencies such as NIH, NSF, DOE, USDA, and DoD, alongside state and industry partnerships. Dedicated commercialization support—through an affiliated foundation and campus offices—provides IP management, licensing, startup mentoring, and flexible, industry-friendly agreements.